Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|August 19, 2013
Why Do Manufacturers Limit the Distribution of Certain Specialty Drugs?
Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.
Advertisement
Some pharmaceutical manufacturers choose a limited distribution model for their specialty product so that they can ensure all standards of care and reporting associated with that therapy are upheld, noted Duane Barnes, senior vice president, consumer delivery, Prime Therapeutics, at the 2013 Armada Specialty Pharmacy Summit.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Ambulatory Pharmacists Convene in Boston at NEIAP's 2026 Annual Forum
4
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
5